Privacy settings

We use technical cookies, that are necessary for the management of the website, statistical cookies and marketing cookies (including third parties cookies) for displaying individual offers and ads. For more information read our Privacy Policy. Statistical cookies and marketing cookies (inclusive of third parties cookies) are used only with your consent. By clicking “Select all and agree” you consent to our use of statistical and/or marketing cookies (inclusive of third parties cookies).

To customize your privacy settings, tick your preferences in the checkboxes and click “Apply selection”. You can always change the privacy settings and deactivate cookies by following the instructions in the Privacy Policy.

Show preferences Select all and accept
IMA is loading

IMA Active @ Inhalation and Respiratory Drug Delivery Conference 2020 • Berlin (Germany), 10-11 September 2020

The event takes place from 10/09/2020 to 11/09/2020

IMA Active @ Inhalation and Respiratory Drug Delivery Conference 2020

IMA Active is pleased to take part in the Inhalation and Respiratory Drug Delivery Conference 2020, which will be held in Berlin (Germany), on September 10-11, 2020.

The conference will bring together experts from pharmaceutical, medical devices manufacturers, biotech industries, academia and regulatory agencies. Besides sharing best practices, this conference will give a great opportunity to discuss about the new challenges of respiratory products and innovative aerosol science including toxicology and modelling.

Presentations will cover a wide spectrum of topics including:

  • Nasal drug delivery.
  • Respiratory drug products analytics and tools.
  • An overview and emerging trends of inhalation and respiratory drug products from inhaled insulin to gene therapy to overcome lung and pulmonary conditions.
  • Alternative therapeutic areas and advancements in combination products.

The key learning points of the Inhalation and Respiratory Drug Delivery Conference are:

  • Future needs for inhaled delivery systems.
  • Overview of respiratory drug market.
  • Drug delivery innovation for respiratory pharmacology.
  • The next generation of drugs combinations.
  • The future potential of the soft mist inhalers for high dose applicants.
  • Challenging requirements and opportunities of the inhalers models on the market.

Alessio Tarozzi, Product Manager for capsule fillers at IMA Active will give a presentation on “Manufacturing Spiriva®: an engineering perspective.

When producing pharmaceutical products in DPI form, industrial manufacturing aspects must be considered together with optimization of the process, as well as to achieve a reliable control method. Precise micro-dosing, gravimetric weight control, containment measures and ease of device assembly are typical issues which could be faced. IMA draws on its extensive expertise to provide the most advanced solutions for DPI processing. Direct weight control performed in line on each single capsule, both before and after filling. Absence of mechanical powder compression for improved airway intake. Accurate micro-dosing and automatic feedback and adjustment. This presentation investigates optimal process parameters for low-dose DPIs achieved by the dosator technology. Both IMA and the customer put in place high qualified resources specialized in mechanical design, statistics and mathematics analysis and software development to explore the best process parameters to achieve the 5.5 mg dose of a powder mix including Tiotropium and a Lactose carrier and optimized it thanks to IMA capsule filling machine model ADAPTA 100 with 100% gravimetric net weight control.

The study proves that a major advantage of using this technology for processing DPIs is that the dosators can be accurately adjusted without any need to compress or aspirate the powder. Maintaining the free-flowing properties of the dispended powder within the capsule better ensures the release of powder from the capsule into the inhaler when the capsule is pierced, thereby better controlling both the emitted dose and the fine particle fraction of the dose discharge from the DPI.

Get in touch

For further information

Other updates

keyboard_arrow_left keyboard_arrow_right